Overall index of data tables

The following overall index lists the tables in the bulletin, the associated graphics and the tables in the annex to the bulletin.

Bulletin tables

Table GPSurvey-1. Lifetime prevalence of drug use among all adults (15-64 years old) in nationwide surveys among the general population

Table GPSurvey-1 Part (i) Lifetime prevalence all adults
Table GPSurvey-1 Part (ii) Survey methods
Table GPSurvey-1 Part (iii) Sources

Table GPSurvey-2. Lifetime prevalence of drug use among young adults (15-34 years old) in nationwide surveys among the general population
Table GPSurvey-3. Last year prevalence of drug use among all adults (15-64 years old) in nationwide surveys among the general population
Table GPSurvey-4. Last year prevalence of drug use among young adults (15-34 years old) in nationwide surveys among the general population
Table GPSurvey-5. Last month prevalence of drug use among all adults (15-64 years old) in nationwide surveys among the general population
Table GPSurvey-6. Last month prevalence of drug use among young adults (15-34 years old) in nationwide surveys among the general population
Table GPSurvey-7. Last 30 days prevalence and frequency of use of cannabis amongst all adults and young adults, according to population surveys

Table GPSurvey-7 Part(i) Last 30 days prevalence (percentage)
Table GPSurvey-7 Part(ii) Frequency of use among all users in last 30 days (percentage)

Table Prevalence-1. School surveys: Lifetime prevalence of psychoactive substance use among 15-16 years old students
Table Prevalence-2. School surveys: prevalence of cannabis use among students aged 15-16 years

Table Prevalence-2 Part (i) Lifetime prevalence (LTP), Last year prevalence (LYP), and Last month prevalence (LMP)
Table Prevalence-2 Part (ii) Use patterns

Table Prevalence-3. Numbers of problem drug users, estimated by various methods, 1995-2002

Table Prevalence-3 Part (i) Numbers of problem drug users
Table Prevalence-3 Part (ii) Numbers of problem drug users assumed to be injecting

Table Prevalence-4. Prevalence of problem drug use (rate per 1000 aged 15-64) estimated by various methods, from 1995 to 2002

Table Prevalence-4 Part (i) Prevalence of problem drug use
Table Prevalence-4 Part (ii) Prevalence of problem drug use assumed to be injecting use

Table Prevalence-0. School surveys: Sources
Table Prison-1. Prevalence of lifetime use of various drugs among prisoners (estimated percentage)
Table Prison-2. Prevalence of lifetime injecting drug use among prisoners (estimated percentage)
Table Prison-3. Prevalence of drug use within prison among prisoners (estimated percentage)
Table Prison-4. Prevalence of injecting drug use within prison among prisoners (estimated percentage)
Annex Table Prison-5 Overall Annex Table of studies of drug use in prisons
Table Prison-0. Prevalence of drug use among prisoners - Sources and Bibligraphic References
Annex Table Prison-5 Overall Annex Table of studies of drug use in prisons
Table IDisease-1. Prevalence of HIV infection among injecting drug users - summary table
Table IDisease-2. Prevalence of HCV infection among injecting drug users - summary table
Table IDisease-3. Prevalence of markers for HBV infection among injecting drug users - summary table
Table IDisease-4. HIV infections newly diagnosed in injecting drug users, by year of report from 1992 to 2003, (a) cases per million population and (b) number of cases
Table IDisease-5. Notified cases of hepatitis C infection among injecting drug users: number of IDUs and percentage of IDUs amongst all cases with known risk factor

Table IDisease-5 Part (i) Notifications IDUs with hepatitis C
Table IDisease-5 Part (ii) Notes and comments

Table IDisease-6. Notified cases of hepatitis B infection among injecting drug users: number of IDUs and percentage of IDUs amongst all cases with known risk factor

Table IDisease-6 Part (i) Notifications of IDUs with hepatitis B
Table IDisease-6 Part (ii) Notes and comments

Table IDisease-7. Incidence of hepatitis C virus antibody among injecting drug users
Annex Table IDisease-8 Prevalence of HIV (%) among IDUs of all ages
Annex Table IDisease-9 Prevalence of HIV (%) among IDUs under 25 years old
Annex Table IDisease-10 Prevalence of HIV (%) among new IDUs
Annex Table IDisease-11 Prevalence of HCV (%) among IDUs of all ages
Annex Table IDisease-12 Prevalence of HCV (%) among IDUs under 25 years old
Annex Table IDisease-13 Prevalence of HCV (%) among new IDUs
Annex Table IDisease-14 Prevalence of current Hepatitis B (% with HbsAg) among IDUs of all ages
Annex Table IDisease-15 Prevalence of antibodies for HBV (%) among IDUs of all ages
Table IDisease-0. Infectious Diseases - Bibliographic References

Table IDisease-0 Part (i) Infectious Diseases - Prevalence
Table IDisease-0 Part (ii) Infectious Diseases - Notifications

Table DRDeath-1. Summary of characteristics of the deceased in drug-related deaths

Table DRDeath-1 Part (i) 2002 or last year with available information
Table DRDeath-1 Part (ii) 1990 or closest year with available information

Table DRDeath-2. Number of acute drug-related deaths recorded in EU member states (15 members up to 2004) according to national definitions, 1985-2002

Table DRDeath-2 Part (i) Total drug-related deaths 1985 onwards
Table DRDeath-2 Part (ii) Male drug-related deaths 1990 to 2002
Table DRDeath-2 Part (iii) Female drug-related deaths 1990 to 2002
Table DRDeath-2 Part (iv) Sources

Table DRDeath-3. Number of acute drug-related deaths recorded in the new EU and other countries according to national definitions, 1990-2002

Table DRDeath-3 Part (i) Total drug-related deaths
Table DRDeath-3 Part (ii) Male and female drug-related deaths

Table DRCrime-1. Number of reports for drug law offences, 1985-2002

Table DRCrime-2. Offence type most involved in the reports for drug law offences in 2002/2001
Table DRCrime-3. Drug types involved in reports for drug law offences: percentage of all reports for drug law offences in 2002/2001
Table DRCrime-4. Percentage of total drug law offences that are related to drug use or possession for use, 1996-2002
Table DRCrime-5. Cannabis-related offences: percentage among total drug law offences, 1996-2002
Table DRCrime-6. Heroin-related offences: percentage among total drug law offences, 1996-2002
Table DRCrime-7. Cocaine-related offences: percentage among total drug law offences, 1996-2002
Table TDI-1. Total numbers of new clients at drug treatment centres, 1996 to 2002
Table TDI-2. Number of cases covered by treatment demand indicator reports, by country and by data source in 2002: New clients and All clients
Table TDI-3. Gender distribution and mean age among new and all clients at out-patient treatment centres in 2002
Table TDI-4. Age distribution (percent) among all clients in treatment by main drug, for those countries supplying data for 2002
Table TDI-5. Distribution of age at first use of main drug by all clients in treatment, from all sources, for those countries supplying data for 2002
Table TDI-6. Distribution of educational level (percentage) among all clients attending out-patient treatment in 2002
Table TDI-7. Distribution of labour status (percentage) amongst all clients attending out-patient treatment in 2002
Table TDI-8. Frequency of cannabis use (in percentages) in the past month amongst all cannabis (primary drug) patients attending outpatient treatment in 2002
Table TDI-9. Secondary drug used: percentage among all cannabis (primary drug) clients attending out-patient treatment in 2002
Table TDI-10. Characteristics of all clients treated for drug problems: demographics and primary drug at treatment in 2002 or most recent year available

Table TDI-10 Part (i) Demographics and injecting status
Table TDI-10 Part (ii) main drug (percentage) and of those the percent injecting it (italics)
Table TDI-10 Part (iii) Sources

Table TDI-11. Characteristics of new clients treated for drug problems: demographics and main drug at treatment in 2002 or most recent year available

Table TDI-11 Part (i) Demographics and injecting status
Table TDI-11 Part (ii) Main drug (percentage) and of those the percent injecting it (italics)

Table TDI-12. Characteristics of all women treated for drug problems in 2002 or most recent year available

Table TDI-12 Part (i) Demographics and injecting status
Table TDI-12 Part (ii) Distribution of primary drug (percentage)

Table TDI-13. Characteristics of all men treated for drug problems in 2002 or most recent year available

Table TDI-13 Part (i) Demographics and injecting status
Table TDI-13 Part (ii) Distribution of primary drug (percentage)

Table Markets-1. Number of cannabis seizures, 1985-2002

Table Markets-1 Part (i) 1994 to 2002
Table Markets-1 Part (ii) 1985 to 2002

Table Markets-2. Quantities of cannabis seized, 1985-2002 (kgs)

Table Markets-2 Part (i) 1994 to 2002
Table Markets-2 Part (ii) 1985 to 2002

Table Markets-3. Number of heroin seizures, 1985-2002

Table Markets-3 Part (i) 1994 to 2002
Table Markets-3 Part (ii) 1985 to 2002

Table Markets-4. Quantities of heroin seized (kgs), 1985-2002

Table Markets-4 Part (i) 1994 to 2002
Table Markets-4 Part (ii) 1985 to 2002

Table Markets-5. Number of cocaine seizures, 1985-2002

Table Markets-5 Part (i) 1994 to 2002
Table Markets-5 Part (ii) 1985 to 2002

Table Markets-6. Quantities of cocaine seized, 1985-2002 (kgs)

Table Markets-6 Part (i) 1994 to 2002
Table Markets-6 Part (ii) 1985 to 2002

Table Markets-7. Number of amphetamines seizures, 1985-2002

Table Markets-7 Part (i) 1994 to 2002
Table Markets-7 Part (ii) 1985 to 2002

Table Markets-8. Quantities of amphetamines seized, 1985-2002 (kgs)

Table Markets-8 Part (i) 1994 to 2002
Table Markets-8 Part (ii) 1985 to 2002

Table Markets-9. Number of ecstasy seizures, 1987-2002

Table Markets-9 Part (i) 1994 to 2002
Table Markets-9 Part (ii) 1987 to 2002

Table Markets-10. Quantities of ecstasy seized, 1985-2002 (tablets)

Table Markets-10 Part (i) 1994 to 2002
Table Markets-10 Part (ii) 1985 to 2002

Table Markets-11. Number of LSD seizures, 1985-2002

Table Markets-11 Part (i) 1994 to 2002
Table Markets-11 Part (ii) 1985 to 2002

Table Markets-12. Quantities of LSD seized, 1985-2002 (doses)

Table Markets-12 Part (i) 1994 to 2002
Table Markets-12 Part (ii) 1985 to 2002

Table Markets-13. Drug seizures in 2002: numbers of seizures and total quantity
Table Markets-14. Price of different illicit drugs at retail level, 2002

Table Markets-14 Part (i) Minimum, maximum and average price in Euros
Table Markets-14 Part (ii) Sources of information

Table Markets-15. Average potency of cannabis resin at retail level, measured as percentage THC content from 1998 to 2002
Table Markets-16. Average potency of herbal cannabis at retail level, measured as percentage THC content from 1998 to 2002

Associated graphics

Evolution of cannabis use (last year prevalence) among young people in some EU countries measured by population surveys
[Figure5OL]. See also Tables GPSurvey-4 and Prevalence-2 Part (i)
Evolution of recent use (past year) of amphetamines and ecstasy among young adults (15-34 years old) in the United Kingdom
[Figure6OL]. See also Table GPSurvey-4
Relative frequency of cannabis (last year prevalence) use among 15-year-old school students who used during past year
[Figure4OL]. See also Table Prevalence-2 Part (ii)

The proportion of people over 35 years among victims of acute drug-related deaths in the EU countries in 1990 and in 2001/2
[Figure10OL]. See also Tables DRDeath-1 Part (i) and Part (ii)
Long-term EU trend in acute deaths directly related to drug use (1985-2001)
[Figure11OL]. See also Table DRDeath-2 Part (i)
Trends in acute drug-related deaths in the different EU countries (1985-2002)
[Figure12OL]. See also Table DRDeath-2 Part (i)

New clients in treatment by year in some EU countries (1996-2002)
[Figure17OL]. See also Table TDI-1
Trends in current injecting drug use amongst heroin users in treatment
[Figure9OL]. See also Tables TDI-10 Part (i) and TDI-11 Part (i)
Distribution of age at first use of main drug by all clients in outpatient treatment in 2002 (in total for those countries supplying data)
[Figure18OL]. See also Table TDI-5
Distribution of educational level amongst all outpatient treatment clients, by country, in 2002
[Figure19OL]. See also Table TDI-6

Annex tables

Annex Table Prevalence-5. Estimates of prevalence from local studies of problem drug use among 15-64 year-olds

Annex Table Prison-5 Overall Annex Table of studies of drug use in prisons

Annex Table IDisease-8 Prevalence of HIV (%) among IDUs of all ages
Annex Table IDisease-9 Prevalence of HIV (%) among IDUs under 25 years old
Annex Table IDisease-10 Prevalence of HIV (%) among new IDUs
Annex Table IDisease-11 Prevalence of HCV (%) among IDUs of all ages
Annex Table IDisease-12 Prevalence of HCV (%) among IDUs under 25 years old
Annex Table IDisease-13 Prevalence of HCV (%) among new IDUs
Annex Table IDisease-14 Prevalence of current Hepatitis B (% with HbsAg) among IDUs of all ages
Annex Table IDisease-15 Prevalence of antibodies for HBV (%) among IDUs of all ages